For example, the recent approval of relatlimab for the treatment of metastatic melanoma as a first-in-class drug targeting LAG3 [78] opens the door for trials with EBVaGC, which are readily justified by the high expression of LAG3 in EBVaGC. This evidence concerns the gene LAG3 and metastatic melanoma.